Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

88 results about "Endocrine therapy" patented technology

Endocrine therapy is a critical part of adjuvant therapy in women with hormone receptor–positive breast cancer, and has been shown to reduce the risk of recurrence and death from breast cancer.

Combination of an ErbB-2 / ErbB-3 bispecific antibody with endocrine therapy for breast cancer

The invention relates to methods of treating of subject that has breast cancer or is at risk of having said cancer, comprising administering to the subject in need thereof a combination of a therapeutically effective amount of an ErbB-2 / ErbB-3 bispecific antibody and a therapeutically effective amount of an endocrine therapy drug, wherein the bispecific antibody has an antigen binding site that can bind an extra-cellular part of ErbB-2 and an antigen binding site that can bind an extra-cellular part of ErbB-3; and to means for said method.
Owner:MERUS NV

Prostate cancer endocrine therapy drug resistance prediction system based on multi-model artificial intelligence

The invention discloses a prostate cancer endocrine therapy drug resistance prediction system based on multi-model artificial intelligence. The prostate cancer endocrine therapy drug resistance prediction system comprises a data acquisition and preprocessing module, a single omics prediction module, a multi-modal feature integration module, a model training module and a prediction result output module. Multi-omics data of a patient is collected and preprocessed, data representations of omics data of different labels are generated by using priori knowledge, and an optimal single-omics prediction model is matched for the omics data of different labels based on the data representations after knowledge enhancement. And constructing a multi-omics prediction model of the prostatic cancer endocrine treatment drug resistance by using the optimal single-omics prediction model corresponding to the different label medical data by adopting Stacking, predicting the drug resistance risk of the patient within a preset time, outputting an early warning, and adjusting the treatment scheme of the patient according to the drug resistance risk. According to the method, the multi-omics data are integrated, the accurate multi-omics prediction model for the drug resistance of the endocrine therapy of the prostate cancer is constructed, and the accuracy and clinical applicability of drug resistance prediction are improved.
Owner:HUNAN PROVINCIAL PEOPLES HOSPITAL

Internal secretion treatment medicine fumigation equipment

The utility model provides an endocrine therapy medicine fumigation device, which belongs to the technical field of medicine fumigation and comprises a fumigator body. The net rack protection plate is positioned in the fumigator body; the two limiting blocks are fixedly connected to the inner walls of the two sides of the fumigator body; the medicine fumigation storage net is slidably connected to the interiors of the two limiting blocks, the internal secretion treatment medicine fumigation equipment can achieve effective fumigation and delivery of internal secretion medicine, through the slidable medicine fumigation storage net, the placement position of the medicine can be easily adjusted according to needs, and the heating degree and fumigation concentration of the medicine can be conveniently controlled; through the design of the first baffle and the second baffle, the release speed of the medicine can be effectively controlled, it is ensured that the medicine is evenly distributed in the fumigation process, and the treatment effect is improved.
Owner:THE SECOND AFFILIATED HOSPITAL OF XINGTAI MEDICAL COLLEGE

Methods and dosing regimens comprising a CDK2 inhibitor for the treatment of cancer

The disclosure provides methods of treating cancer in a subject in need thereof comprising administering to the subject a therapeutically effective amount of PF-07104091, as a monotherapy or in combination with an endocrine therapy agent and / or a CDK4 / 6 inhibitor.
Owner:PFIZER INC

Traditional Chinese medicine preparation for treating climacteric syndrome in breast cancer endocrine therapy

The invention provides a traditional Chinese medicine preparation for treating climacteric syndrome in breast cancer endocrine therapy, and belongs to the technical field of traditional Chinese medicine preparations. The traditional Chinese medicine preparation comprises 9-12 g of radix bupleuri, 9-15 g of scutellaria baicalensis, 9-15 g of rhizoma pinelliae preparata, 15-30 g of codonopsis pilosula, 9-15 g of cassia twig, 9-15 g of radix paeoniae alba, 9-15 g of calcined dragon bone, 9-15 g of calcined oyster shell, 15-30 g of rhizoma acori graminei, 9-15 g of radix curcumae, 9-15 g of roasted turtle shell, 9 g of ginger and 9 g of jujube. The traditional Chinese medicine preparation can effectively relieve symptoms such as chest and hypochondrium distension and stuffiness, depression, dysphoria and other emotion regulation, hypochondrium pain and the like of patients with breast cancer endocrine therapy climacteric syndromes.
Owner:SHANXI PROVINCE CHINESE MEDICINE RESEARCH INSTITUTE

Methods for treating breast cancer

PendingCN121013734AOrganic active ingredientsPeptide/protein ingredientsEndocrine therapyRadiopharmaceutical Compound
The present disclosure relates to methods of treating breast cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a radiopharmaceutical compound having a GRPR antagonist moiety, such as [177Lu] Lu-NeoB, in combination with a CDK4 / 6 inhibitor, such as ribociclib, and a therapeutically effective amount of an endocrine therapy, such as fulvestrant.
Owner:NOVARTIS AG

Application of PGK1 inhibitor in preparation of medicine for treating MYC oncogene amplification type prostatic cancer

The invention discloses an application of a PGK1 inhibitor in preparation of a medicine for treating MYC (myelodysplastic cancer) oncogene amplification type prostate cancer, it is found for the first time that PGK1 is a stable target for patent medicine, the PGK1 inhibitor NG-52 can effectively inhibit growth of MYC oncogene amplification type prostate cancer cells, and the target targets a glycolytic pathway, has small influence on aerobic respiratory metabolism of normal cells in a body, and can be used for preparing a medicine for treating MYC oncogene amplification type prostate cancer. The safety is higher; the mechanism of the target is different from that of current advanced prostate cancer chemotherapy drugs and endocrine therapy drugs, and the target has great potential of combined treatment with current first-line drugs, is easy to popularize and use clinically, and provides better prognosis for MYC gene amplification type prostate cancer patients.
Owner:SHANGHAI FIRST PEOPLES HOSPITAL

Panel of ER regulated genes for use in monitoring endocrine therapy in breast cancer

The present disclosure relates to a panel of ER regulated genes and method for using the panel for monitoring the response of an individual having cancer to treatment with amcenestrant, the method comprising determining a first ER activity score from a sample from the individual at a first time point before treatment with amcenestrant using the panel, then determining a second ER activity score from a sample from the individual at a second time point following administration of amcenestrant using the panel, and comparing the first ER activity score with the second ER activity score, wherein a decrease in the second ER activity score relative to the first ER activity score is predictive of target engagement of amcenestrant.
Owner:SANOFI SA(FR)

Use of sglt2 inhibitors for the preparation of a medicament for the treatment of a hormone receptor low responsive reproductive system disease

ActiveCN117018203BOrganic active ingredientsSexual disorderDiseaseTherapeutic Hormone
The present application relates to a kind of SGLT2 inhibitor in the preparation for treating hormone receptor low reaction type reproductive system disease in the application of drug, in particular, SGLT2 inhibitor and hormone can improve or enhance the sensitivity and / or for reversing the drug resistance of endocrine therapy drug, such as hormone, can enhance the therapeutic effect of such drug, especially in drug-resistant reproductive system disease and tumor treatment has good application prospect.
Owner:SHANGHAI INST FOR BIOMEDICAL & PHARM TECH

Targeted measure of transcriptional activity related to hormone receptors

Provided herein are methods of determining tumoral sensitivity to hormonal (endocrine) therapy based upon an index of estrogen receptor (ER)- and progesterone receptor (PR)-related genes, referred to as the sensitivity to endocrine therapy index (SETER / PR index), and may have additional consideration for the proportion of ER gene (ESR1) RNA transcripts that contain a mutation relative to the value of the SETER / PR index. Further provided are methods of treating breast cancer patients determined to be sensitive to an endocrine therapy by the SETER / PR index.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST +1

Diagnostic and therapeutic approaches used to treat breast cancer

In particular, predictive diagnostic methods, pharmacodynamic methods, and therapeutic methods for treating breast cancer are provided herein. In an embodiment, the methods and compositions are based at least in part on the following findings: an estradiol (E2) induction score or an estrogen receptor (ER) pathway activity score determined from a sample from an individual (e.g., a tissue sample, such as a tumor tissue sample, such as a FFPE, FF, archived, fresh, or frozen tumor tissue sample) can be used to determine whether the individual with breast cancer is likely to respond to a treatment including endocrine therapy; can be used in a method for selecting a therapy for an individual with breast cancer; can be used in a method for treating an individual with breast cancer; can be used in a method for monitoring the therapeutic effect of endocrine therapy, and can be used in a related kit.
Owner:GENENTECH INC

Post-treatment breast cancer prognosis

The disclosure includes the identification and use of gene expression profiles, or patterns, with clinical relevance to extended treatment and cancer-free survival in a patient. In particular, the disclosure includes the identities of genes that are expressed in correlation with benefit in a switch in endocrine therapy used to treat a patient. The levels of gene expression are disclosed as a molecular index for predicting clinical outcome, and so prognosis, for the patient. The disclosure further includes methods for predicting cancer recurrence, and / or predicting occurrence of metastatic cancer, after initial treatment with an anti-estrogen agent. The disclosure further includes methods for determining or selecting the treatment of a subject based upon the likelihood of life expectancy, cancer recurrence, and / or cancer metastasis.
Owner:BIOTHERANOSTICS INC +1

A novel endocrine therapy resistance marker for advanced prostate cancer and its application

The present invention relates to the field of medicine, and discloses a novel endocrine therapy resistance marker for advanced prostate cancer and its application, wherein the marker is DENND3. The present invention first discovered that the expression level of the DENND3 gene in prostate cancer abiraterone-resistant cells is significantly higher than that in parental prostate cancer cells. Therefore, the determination of the expression level of the DENND3 gene can be used as a basis for judging the drug resistance / sensitivity of the user to abiraterone; the DENND3 gene-specific siRNAs provided by the present invention can efficiently inhibit or knock down the expression of the DENND3 gene in target cells, thereby promoting cell apoptosis, inhibiting the proliferation of abiraterone-resistant prostate cancer cells, and further inhibiting the growth of prostate cancer cells. Therefore, it can be used to prepare a drug that improves the resistance of prostate cancer to abiraterone, and has great clinical and economic value in the treatment of prostate cancer.
Owner:HUNAN PROVINCIAL PEOPLES HOSPITAL

Hydroxyphenyl-indoline-2-one cancer therapeutics

Small molecule ERα biomodulators that kill therapy-resistant ERα positive breast, ovarian, and endometrial cancer cells are disclosed. In one embodiment, the small molecule biomodulator has increased therapeutic utility because of an increased ability to kill therapy-resistant cancer cells compared to BHPI and other conventional therapies (endocrine therapies, tamoxifen, and fulvestrant / ICI). The small molecule biomodulators not only inhibit proliferation of the cancer cells but kills them, which prevents reactivation of tumors years later. Compounds of the invention, such as ErSO-TFPy, are effective for treating ERα positive cancers such as breast cancer, ovarian cancer, uterine cancer, cervical carcinoma, endometrial cancer, and the like.
Owner:THE BOARD OF TRUSTEES OF THE UNIV OF ILLINOIS

Internal secretion treatment medicine fumigation equipment

The utility model relates to the technical field of medicine fumigation equipment, in particular to endocrine treatment medicine fumigation equipment which comprises a treatment box, the outer wall of one side of the treatment box is open, a drawer is installed on the inner wall of the bottom of the treatment box in a sliding mode, and the same partition plate is fixedly installed on the inner walls of the two sides of the treatment box. The partition plate is located above the treatment box, the same mounting frame is slidably mounted on the inner walls of the two sides of the treatment box, an air driving mechanism is arranged in the mounting frame, and the air driving mechanism comprises a plurality of exhaust fans. According to the medicine aromatherapy device, the defects in the prior art are overcome, under the matching action of the exhaust fans and the like, the multiple exhaust fans are turned on and rotate, so that aromatherapy steam in the drawer can be exhausted through the partition plate and the air outlet in the treatment box, medicine aromatherapy steam treatment is carried out on a patient, and the medicine aromatherapy effect is good. Therefore, the steam exhaust efficiency is improved, long treatment time is not needed, and the treatment effect is good.
Owner:WUXI NAIS PHARM TECH CO LTD

Pharmaceutical composition and application thereof

The invention belongs to the technical field of medicines, and relates to a pharmaceutical composition and application thereof. The invention specifically relates to a novel endocrine therapeutic drug comprising (a) a compound of general formula (I) or a pharmaceutically acceptable salt, isomer or crystal form thereof, and (b) a novel endocrine therapeutic drug, each variable in the general formula being as defined in the specification. Research finds that the compound shown in the general formula (I) or the pharmaceutically acceptable salt, isomer or crystal form of the compound and a novel endocrine therapeutic drug have a synergistic effect in treatment of prostatic cancer; # imgabs0 #
Owner:TRANSTHERA SCIENCES (NANJING) INC

Biomarkers and therapeutics for endocrine therapy resistance

Cancer cells can develop resistance to endocrine therapies, such as Tamoxifen, through acquisition of the Y537S mutation. Cells transfected with the Y537S mutation showed significant increases in mitochondrial mass and membrane potential, consistent with an increase in mitochondrial biogenesis. Certain biomarkers are identified that have prognostic value of endocrine therapy resistance. The mechanism resulting in this resistance, however, leaves these treatment-resistant cells vulnerable to therapeutics that inhibit mitochondrial biogenesis. Numerous mitochondrial biogenesis inhibitors are disclosed, as well as methods for reducing or eliminating endocrine treatment resistance, improving the effectiveness of an endocrine therapy, and for treating cancer.
Owner:LUNELLA BIOTECH INC

Post-treatment breast cancer prognosis

The disclosure includes the identification and use of gene expression profiles, or patterns, with clinical relevance to extended treatment and cancer-free survival in a patient. In particular, the disclosure includes the identities of genes that are expressed in correlation with benefit in a switch in endocrine therapy used to treat a patient. The levels of gene expression are disclosed as a molecular index for predicting clinical outcome, and so prognosis, for the patient. The disclosure further includes methods for predicting cancer recurrence, and / or predicting occurrence of metastatic cancer, after initial treatment with an anti-estrogen agent. The disclosure further includes methods for determining or selecting the treatment of a subject based upon the likelihood of life expectancy, cancer recurrence, and / or cancer metastasis.
Owner:BIOTHERANOSTICS INC +1

Traditional Chinese medicine filtering device for internal medicine endocrine therapy of traditional Chinese medicine

The invention relates to the technical field of traditional Chinese medicine equipment, in particular to a traditional Chinese medicine filtering device for internal Chinese medicine endocrine therapy, which comprises a primary filter with a cavity structure, a peristaltic filter element arranged in the primary filter, a liquid inlet arranged at the top of the primary filter and a discharge port arranged at the bottom of the primary filter, electric control valves are respectively arranged in the medicine inlet, the first slag discharge port and the discharge port; the primary filter is also provided with a filter element driver; the fine filters are communicated with the discharging opening through electric control valves, each fine filter is of a cavity structure, a ceramic separation membrane is arranged in each fine filter, and a fine filter opening is formed in the bottom of each fine filter; the molecular sieve is of a longitudinal cavity structure, the top of the molecular sieve is provided with a high-pressure connector, the high-pressure connector is communicated with the fine filtration opening through a high-pressure pump, and the molecular sieve is provided with a medicine outlet. Through a multi-stage precise separation technology and a dynamic anti-blocking design, the purification problem of the traditional Chinese medicine decoction is systematically solved, and the traditional Chinese medicine stability of endocrine disease patients is ensured.
Owner:SHAANXI PROVINCIAL HOSPITAL OF CHINESE MEDICINE

Application of LINC02568 as target in preparation of ER + breast cancer treatment kit

The invention discloses an application of LINC02568 as a target in preparation of an ER < + > breast cancer treatment kit. The reagent targeting LINC02568 can effectively inhibit in-vitro growth of ER < + > breast cancer cells and in-vivo tumor formation, and can be combined with an endocrine therapeutic drug or a small-molecule inhibitor targeting CA12 to achieve a synergistic inhibition effect on growth of cells and tumors.
Owner:XIAMEN UNIV

Transcriptional reprogramming differentiates active from inactive esr1 fusions in endocrine therapy-refractory metastatic breast cancer

Methods of treatment, methods of detection, and kits associated with ERα+ cancer, such as ERα+ breast cancer, are disclosed herein. The methods and kits disclosed herein can assist physicians in relieving patient suffering by identifying cancer estrogen receptor status, and identifying appropriate therapeutic regimens in an individualized manner.
Owner:BAYLOR COLLEGE OF MEDICINE

Multi-targeting photothermal-photodynamic-endocrine three-mode synergistic breast cancer treatment nano-drug and application thereof

The invention discloses a multi-targeting photothermal-photodynamic-endocrine three-mode synergistic breast cancer treatment nano-drug and application thereof, and relates to the technical field of biology and new medicine. Growth and metastasis of breast cancer cells are effectively inhibited through the synergistic effect of three modes of photo-thermal, photodynamic and endocrine therapy, the amphiphilic polymer designed based on Tcpp (tetracarboxylphenylporphyrin) can be self-assembled to form a nanoscale hollow regular sphere, and by means of the high permeability and retention effect (EPR effect) of a tumor site, the tumor site can be effectively inhibited, and the tumor site can be effectively inhibited. The efficient accumulation of the medicine in the tumor tissue is realized; the prodrug BHP is combined with a photo-thermal group and palbociclib, so that the synergistic interaction of multiple action mechanisms is realized, and the treatment effect is improved. The nano-drug prepared by the invention has good safety and biocompatibility, shows a remarkable anti-tumor effect in a tumor-bearing nude mouse model, and provides a brand new strategy and thought for treatment of breast cancer.
Owner:JIANGXI SCI & TECH NORMAL UNIV

Serum 7-dehydrocholesterol as marker for diagnosing prostatic cancer metastasis and endocrine therapy drug resistance and application of serum 7-dehydrocholesterol

The invention belongs to the technical field of prostate cancer diagnosis, and particularly relates to serum 7-dehydrocholesterol as a prostate cancer metastasis and endocrine treatment drug resistance diagnosis marker and application thereof. 7-dehydrocholesterol provided by the invention has different levels in human prostate cancer cell lines such as LNCaP, Du145, PC3 and the like, and is abnormally increased in PC3, so that the 7-dehydrocholesterol can be used as a drug resistance diagnosis marker for prostate cancer metastasis and endocrine therapy; the reagent composition capable of specifically recognizing 7-dehydrocholesterol and generating detectable signals can be used for preparing a prostate cancer detection kit; the 7-dehydrocholesterol provided by the invention has non-invasive, non-invasive and efficient effects as a diagnostic marker, and solves the technical problem of lack of a prostate cancer diagnostic marker in the prior art.
Owner:THE FIFTH AFFILIATED HOSPITAL SUN YAT SEN UNIV

Therapeutic and prophylactic method for tumor treatable with endocrine therapy by combined use of fibroblast growth factor receptor inhibitor with endocrine therapy

To provide a novel therapeutic method exhibiting significantly excellent antitumor effect to a tumor treatable with endocrine therapy by using a FGFR inhibitor.SOLUTION: Provided is a novel treatment method for cancer tumors to which endocrine therapy is to be applied, using an FGFR inhibitor (S)-1-(3-(4-amino-3-((3,5-dimethoxyphenyl)ethynyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)pyrrolidin-1-yl)prop-2-en-1-one or a pharmaceutically acceptable salt thereof. Further provided are a pharmaceutical composition comprising the above compound or a pharmaceutically acceptable salt thereof for use in treatment and / or prevention of tumors to which endocrine therapy is applicable, as well as related compounds, uses, methods, and combinations.SELECTED DRAWING: None
Owner:TAIHO PHARMA CO LTD

Primer probe combination for detecting ESR1 gene drug-resistant mutation site based on digital PCR single tube and application of primer probe combination

The invention discloses a primer and probe combination for detecting ESR1 gene drug-resistant mutation sites based on a digital PCR single tube and application of the primer and probe combination, and belongs to the technical field of molecular detection, sequences of primers are shown as SEQ ID NO.1-2, sequences of probes are shown as SEQ ID NO.3-4, and 5'ends of the two probes are marked with different fluorophores. According to the present invention, with the primer probe combination, the high-sensitivity and rapid detection of the common nine drug-resistant related mutation sites such as L536H, L536Q, L536R, L536P, Y537S, Y537C, Y537N, Y537D and D538G of the ESR1 gene in the breast cancer through the single tube can be achieved, such that the ESR1 gene detection efficiency is substantially improved, and the detection cost is reduced so as to guide the endocrine treatment of the breast cancer.
Owner:XIAMEN SPACEGEN BIOTECH CO LTD

Combination therapy using CDK4 inhibitors for cancer treatments

PCT designated stageWO2026025013A2Organic active ingredientsAntibody ingredientsAntiendomysial antibodiesCyclin-dependent kinase 4
This disclosure relates to combination therapies comprising a cyclin dependent kinase 4 (CDK4) inhibitor of Formula (I) disclosed herein, and a monoclonal antibody or an antibody-drug conjugate, optionally in further combination with an endocrine therapy agent, and associated methods of treatment, pharmaceutical compositions, and uses thereof.
Owner:PFIZER INC +1

Methods of treating breast cancer using selective estrogen receptor degradation agents (SERDs)

The present invention relates to methods of treating breast cancer using selective estrogen receptor degradation agents (SERD). The present specification relates to methods of treating hormone receptor positive (HR +), human epidermal growth factor receptor 2 negative (HER2-), metastatic, or localized region recurrent breast cancer comprising administering to a patient suffering from such cancer a next generation selective estrogen receptor degrading agent (ngSERD), such as carmistrant, such as carmistrant. Characterized in that the cancer has relapsed or progressed after at least one past endocrine treatment line.
Owner:ASTRAZENECA AB

Methods for predicting effects of dose intense chemotherapy treatments

PCT designated stage expiredWO2024227177A3Organic active ingredientsHormone peptidesEndocrine therapyPR - Progesterone receptor
Provided herein are methods of determining sensitivity to dose intense chemotherapy regimens based upon an index of estrogen receptor (ER)- and progesterone receptor (PR)-related genes, referred to as the sensitivity to endocrine therapy index (SETER / PR index). Further provided are methods of treating cancer patients determined to be sensitive to dose intense chemotherapy therapy by the SETER / PR index. Also provided herein are methods for determining prognosis based on the SET2,3 index.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST +2